Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Keuhkojen pahenemisvaiheiden virtaviivaistettu hoito pediatriassa (STOP PEDS RCT)

Keuhkojen pahenemisvaiheiden virtaviivainen hoito pediatriassa satunnaistettu kontrolloitu tutkimus (STOP PEDS RCT)

The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

The STOP PEDS pilot study demonstrated that a randomized trial of treatment strategies for mild pulmonary exacerbations (PEx) in children with CF was feasible and that assignment to a tailored therapy arm (defined below) may reduce antibiotic exposure.

Based on the research priorities identified by CF families and clinicians and the results of the pilot study, the STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient PEx in the pediatric CF population. The two treatment arms are immediate antibiotics and tailored therapy. In both arms, participants will be instructed to increase airway clearance at the onset of an eligible PEx. In the immediate antibiotics arm, they will also begin 14 days of oral antibiotics preselected by their primary CF providers, while in the tailored therapy they will only begin antibiotics if prespecified criteria for worsening symptoms or failure to improve are met.

The STOP PEDS study will enroll three cohorts. In the main cohort, children ages 6-18 on highly effective modulator therapy (HEMT) will be enrolled when well and followed for 12 months. Participants will be randomly assigned to a treatment arm and maintain that treatment assignment for all subsequent eligible PEx during their 12-month enrollment period. Two additional pilot cohorts, the preschool cohort (children ages 3 to 5 on HEMT) and the non-HEMT cohort (children ages 6-18 not eligible for HEMT), will be enrolled in parallel pilot studies. Participants will enroll when well and be followed through one randomized PEx.

Participants in the STOP PEDS RCT at selected sites will have the opportunity to enroll in optional substudies if eligible. These substudies include:

  • Clinic throat swab substudy
  • Home throat and nasal swab substudy
  • Remote monitoring substudy (Home monitoring of lung function, vital signs, activity and sleep)

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

430

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

  • Nimi: Erika Enright
  • Puhelinnumero: 206-897-1922
  • Sähköposti: eenright@uw.edu

Opiskelupaikat

    • British Columbia
      • Vancouver, British Columbia, Kanada, V6H 3V4
        • Rekrytointi
        • British Columbia Children's Hospital
        • Päätutkija:
          • Jonathan Rayment, MD
        • Ottaa yhteyttä:
    • Ontario
      • Toronto, Ontario, Kanada, M5G 0A4
        • Rekrytointi
        • The Hospital for Sick Children & Toronto Canada CF Centre Pediatrics
        • Päätutkija:
          • Felix Ratjen, MD
        • Ottaa yhteyttä:
    • Alabama
      • Birmingham, Alabama, Yhdysvallat, 35233
        • Rekrytointi
        • The Children's Hospital Alabama & University of Alabama at Birmingham
        • Päätutkija:
          • Christopher Fowler, MD
        • Ottaa yhteyttä:
    • Arizona
      • Tucson, Arizona, Yhdysvallat, 85713
        • Rekrytointi
        • Tucson Cystic Fibrosis Center
        • Päätutkija:
          • Cori Daines, MD
        • Ottaa yhteyttä:
    • California
      • Los Angeles, California, Yhdysvallat, 90027
        • Rekrytointi
        • Children's Hospital of Los Angeles & Anton Yelchin Cystic Fibrosis Clinic
        • Päätutkija:
          • Martha McKinney, MD
        • Ottaa yhteyttä:
      • Palo Alto, California, Yhdysvallat, 94304
        • Rekrytointi
        • Stanford University
        • Ottaa yhteyttä:
        • Päätutkija:
          • Lori WaiHang Lee, MD
      • San Diego, California, Yhdysvallat, 92123
        • Ei vielä rekrytointia
        • Rady Children's Hospital at University of California San Diego
        • Ottaa yhteyttä:
        • Päätutkija:
          • Kathryn Akong, MD
    • Colorado
      • Aurora, Colorado, Yhdysvallat, 80045
    • Georgia
      • Atlanta, Georgia, Yhdysvallat, 30322
        • Rekrytointi
        • Children's Healthcare of Atlanta & Emory University
        • Ottaa yhteyttä:
        • Päätutkija:
          • Ajay Kasi, MD
    • Illinois
      • Chicago, Illinois, Yhdysvallat, 60611
        • Rekrytointi
        • Ann & Robert H. Lurie Children's Hospital of Chicago & Northwestern University
        • Päätutkija:
          • Maria Dowell, MD
        • Ottaa yhteyttä:
    • Indiana
      • Indianapolis, Indiana, Yhdysvallat, 46202
        • Rekrytointi
        • Riley Hospital for Children & Indiana University
        • Ottaa yhteyttä:
        • Päätutkija:
          • D. B. Sanders, MD, MS
        • Ottaa yhteyttä:
    • Iowa
      • Iowa City, Iowa, Yhdysvallat, 52242
        • Rekrytointi
        • University of Iowa
        • Ottaa yhteyttä:
        • Päätutkija:
          • Anthony Fischer, MD
    • Maryland
      • Baltimore, Maryland, Yhdysvallat, 21287
        • Rekrytointi
        • Johns Hopkins Hospital, Johns Hopkins University
        • Ottaa yhteyttä:
        • Päätutkija:
          • Peter Mogayzel, MD, PhD, MBA
    • Massachusetts
      • Boston, Massachusetts, Yhdysvallat, 02115
        • Rekrytointi
        • Boston Children's Hospital & Harvard University
        • Ottaa yhteyttä:
        • Päätutkija:
          • Gregory Sawicki, MD
    • Michigan
      • Ann Arbor, Michigan, Yhdysvallat, 48109-5212
        • Rekrytointi
        • University of Michigan Health System
        • Ottaa yhteyttä:
        • Päätutkija:
          • Samya Nasr, MD
    • Minnesota
      • Minneapolis, Minnesota, Yhdysvallat, 55404
        • Rekrytointi
        • Children's Hospitals and Clinics of Minnesota
        • Päätutkija:
          • Brooke Moore, MD
        • Ottaa yhteyttä:
      • Minneapolis, Minnesota, Yhdysvallat, 55455
        • Rekrytointi
        • The Minnesota Cystic Fibrosis Center & University of Minnesota
        • Päätutkija:
          • Samuel Goldfarb, MD
        • Ottaa yhteyttä:
    • Missouri
      • Kansas City, Missouri, Yhdysvallat, 64108
        • Rekrytointi
        • Children's Mercy Hospital
        • Ottaa yhteyttä:
        • Päätutkija:
          • Hugo Escobar, MD
      • St Louis, Missouri, Yhdysvallat, 63110
        • Rekrytointi
        • St. Louis Children's Hospital & Washington University School of Medicine
        • Päätutkija:
          • Jessica Pittman, MD
        • Ottaa yhteyttä:
    • New York
      • Rochester, New York, Yhdysvallat, 14642
        • Rekrytointi
        • University of Rochester Medical Center Strong Memorial
        • Ottaa yhteyttä:
        • Päätutkija:
          • Matthew McGraw, MD
    • North Carolina
      • Chapel Hill, North Carolina, Yhdysvallat, 27514
        • Rekrytointi
        • University of North Carolina at Chapel Hill
        • Päätutkija:
          • Jennifer Goralski, MD
        • Ottaa yhteyttä:
    • Ohio
      • Cincinnati, Ohio, Yhdysvallat, 45229
        • Rekrytointi
        • Cincinnati Children's Hospital Medical Center
        • Päätutkija:
          • Gary McPhail, MD
        • Ottaa yhteyttä:
    • Oregon
      • Portland, Oregon, Yhdysvallat, 97239-3098
        • Rekrytointi
        • Oregon Health & Science University
        • Ottaa yhteyttä:
        • Päätutkija:
          • Kelvin MacDonald, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Yhdysvallat, 19104
        • Rekrytointi
        • Children's Hospital of Philadelphia & University of Pennsylvania
        • Päätutkija:
          • Clement Ren, MD, MBA
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
      • Pittsburgh, Pennsylvania, Yhdysvallat, 15224
        • Rekrytointi
        • Children's Hospital of Pittsburgh of UPMC & University of Pittsburgh Medical Center
        • Päätutkija:
          • Daniel Weiner, MD
        • Ottaa yhteyttä:
    • South Carolina
      • Charleston, South Carolina, Yhdysvallat, 29425
        • Rekrytointi
        • Medical University of South Carolina
        • Päätutkija:
          • Sylvia E Szentpeter, MD
        • Ottaa yhteyttä:
          • Anushka Phadke, CRC
          • Puhelinnumero: 843-792-4656
          • Sähköposti: phadke@musc.edu
        • Ottaa yhteyttä:
    • Texas
      • Dallas, Texas, Yhdysvallat, 75235
        • Rekrytointi
        • University of Texas Southwestern & Children's Health
        • Päätutkija:
          • Preeti Sharma, MD
        • Ottaa yhteyttä:
      • Houston, Texas, Yhdysvallat, 77030
        • Rekrytointi
        • Texas Children's Hospital & Baylor College of Medicine
        • Päätutkija:
          • Fadel Ruiz, MD
        • Ottaa yhteyttä:
    • Vermont
      • Burlington, Vermont, Yhdysvallat, 05401
        • Rekrytointi
        • Vermont Children's Hospital & University of Vermont Medical Center
        • Päätutkija:
          • Thomas Lahiri, MD
        • Ottaa yhteyttä:
    • Virginia
      • Richmond, Virginia, Yhdysvallat, 23298
        • Rekrytointi
        • Virginia Commonwealth University
        • Ottaa yhteyttä:
        • Päätutkija:
          • Michael T. Schechter, MD
    • Washington
      • Seattle, Washington, Yhdysvallat, 98105
    • Wisconsin
      • Madison, Wisconsin, Yhdysvallat, 53792
        • Rekrytointi
        • University of Wisconsin
        • Päätutkija:
          • Hara Levy, MD
        • Ottaa yhteyttä:
      • Milwaukee, Wisconsin, Yhdysvallat, 53226
        • Rekrytointi
        • Children's Wisconsin & Medical College of Wisconsin
        • Päätutkija:
          • Nicholas Antos, MD
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

3 vuotta - 18 vuotta (Lapsi, Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  1. Age

    1. For main cohort and non-HEMT cohort: age 6 to <19 years
    2. For preschool cohort: age 3 to <6 years
  2. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:

    1. sweat chloride ≥ 60 mEq/liter
    2. two disease-causing variants in the cystic fibrosis transmembrane conductive regulator (CFTR) gene
  3. Written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability of participant to comply with the requirements of the study

  4. Highly Effective Modulator Therapy

    1. For main cohort and preschool cohort: Taking HEMT for at least 3 months at enrollment
    2. For non-HEMT cohort: not eligible for HEMT based on CFTR genotype or eligible but not taking for at least 3 months and no plans to start HEMT in the next year, and also not taking tezacaftor-ivacaftor or lumacaftor-ivacaftor for at least 3 months
  5. For main cohort and non-HEMT cohort: able to perform acceptable and reproducible spirometry

  6. For main cohort and non-HEMT cohort: ppFEV1 ≥ 50% predicted at enrollment based on the Global lung Initiative (GLI) reference equations

  7. Ability to receive text messages and access the internet

Exclusion Criteria:

  1. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the individual or the quality of the data
  2. Receiving an acute course of oral or IV antibiotics at the time of enrollment or within the 14 days prior to enrollment. Individuals may be re-screened ≥21 days after completion of antibiotics if they are at their baseline state of health, per self-report
  3. Treatment with systemic corticosteroids at enrollment or within the 14 days prior to enrollment. Individuals may be re- screened ≥21 days after completion of systemic corticosteroids if they are at their clinical baseline, per self-report
  4. History of solid organ transplant
  5. History of positive culture for Mycobacterium abscessus in the 12 months prior to enrollment
  6. Treatment with antibiotics for any non-tuberculous mycobacteria (NTM) at enrollment
  7. Three or more IV antibiotic-treated PEx in the 12 months prior to enrollment
  8. Treatment with chronic oral antibiotics other than azithromycin at enrollment
  9. Treatment with systemic corticosteroids for allergic bronchopulmonary aspergillosis (ABPA) in the 12 months prior to enrollment

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Immediate Antibiotics

Increased airway clearance plus early initiation of oral antibiotics

Increase airway clearance and start 14 days of preselected oral antibiotics right away

Kokeellinen: Tailored Therapy

Increased airway clearance alone, with addition of oral antibiotics for worsening symptoms or failure to improve

Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
One-year change in pulmonary function by spirometry-measured ppFEV1
Aikaikkuna: 1 year

Compare the difference in pulmonary function between arms by evaluating change in spirometry-measured percent predicted forced expiratory volume (ppFEV1). A spirometry test measures the amount of air a person can forcibly exhale after a deep breath (forced vital capacity, or FVC) and the amount of air they can exhale in one second (forced expiratory volume in one second, or FEV1). A lower measured value compared to the reference value indicates lung disease.

1 year

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
One-Year change in pulmonary function by LCI
Aikaikkuna: 1 year

Compare the difference in pulmonary function between arms by evaluating change in Lung Clearance Index (LCI). LCI increases when there is lung disease, which causes ventilation inhomogeneity. LCI is calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity [FRC]) required to reduce end-tidal nitrogen concentration to 1/40th of the original level.

1 year

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Recovery to baseline by ppFEV1 and CRISS following a PEx
Aikaikkuna: 28 days

Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx), by spirometry-measured percent predicted forced expiratory volume (ppFEV1), and after all pulmonary exacerbations, measured by CRISS symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

28 days
Recovery to baseline by Lung Clearance Index (LCI)
Aikaikkuna: 28 days

Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx) in LCI, and after all exacerbations for symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

28 days
Safety Endpoint 1: Cumulative oral antibiotic exposure
Aikaikkuna: 1 year

Compare cumulative oral antibiotic exposure in each treatment arm.

1 year
Safety Endpoint 2: Number of respiratory illnesses
Aikaikkuna: 1 year

Compare the number of respiratory illnesses reported over the study period in each treatment arm.

1 year
Safety Endpoint 3: Proportion of respiratory illnesses treated with antibiotics during PEx
Aikaikkuna: 28 days

Compare the proportion of respiratory illnesses treated with antibiotics during the 28-day pulmonary exacerbation (PEx) treatment period in each treatment arm.

28 days
Safety Endpoint 4: Number of PEx treated with IV antibiotics
Aikaikkuna: 1 year

Compare the number of pulmonary exacerbations (PEx) treated with IV antibiotics over the study period in each treatment arm.

1 year
Safety Endpoint 5: Proportion of PEx failing to recover to baseline symptoms at Day 28
Aikaikkuna: 28 days

Compare the proportion of pulmonary exacerbations (PEx) failing to recover to baseline symptoms at Day 28 in each treatment arm.

28 days
Safety Endpoint 6: Proportion of PEx with ppFEV1 below baseline at Day 28
Aikaikkuna: 1 year

Compare the proportion of pulmonary exacerbations (PEx) with spirometry-measured percent predicted forced expiratory volume (ppFEV1) below baseline at Day 28 in each treatment arm.

1 year
Safety Endpoint 7: Time from initial randomized PEx to next respiratory illness
Aikaikkuna: 1 year

Compare the time from initial randomized pulmonary exacerbation (PEx) to next respiratory illness in each treatment arm.

1 year
Safety Endpoint 8: Targeted adverse events (patient report of antibiotic side effects during PEx)
Aikaikkuna: 1 year

Compare the targeted adverse events (patient report of antibiotic side effects during pulmonary exacerbation period) in each treatment arm.

1 year
Safety Endpoint 9: Treatment-emergent CF microorganisms on clinical respiratory cultures
Aikaikkuna: 1 year

Compare treatment-emergent CF microorganisms on clinical respiratory cultures in each treatment arm.

1 year
Qualitative Assessment 1: Caregivers' experience managing study treatment
Aikaikkuna: 1 year

To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences.

1 year
Qualitative Assessment 2: Study treatment impact on child and family daily life
Aikaikkuna: 1 year

To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will evaluate study treatment impact on child and family daily life and report themes that emerge regarding caregivers' experiences.

1 year
Health care costs 1: Total estimated cost of antibiotics
Aikaikkuna: 1 year

Compare total estimated cost of antibiotics used over the course of the study between treatment arms.

1 year
Health care costs 2: Health care utilization
Aikaikkuna: 1 year

Compare health care utilization over the course of the study between treatment arms, including number of primary care visits and number of emergency room visits.

1 year
Health care costs 3: Parent work productivity measures (WPAI)
Aikaikkuna: 1 year

To compare parent Work Productivity and Activity Impairment (WPAI) measures between study arms. The WPAI includes four scores assessing absenteeism, presenteeism, work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment in the last seven days. Scores range from 0 to 100, with higher scores indicating greater impairment.

1 year
Preschool and non-HEMT Pilot Cohort Primary Feasibility
Aikaikkuna: 28 days

Estimate the proportion of preschool and non-HEMT (Highly Effective Modulator Therapy) participants randomized to the tailored therapy arm that has no antibiotic exposure in the 28 days following a pulmonary exacerbation (PEx).

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 1: ppFEV1 and LCI recovery
Aikaikkuna: 28 days

Compare percent predicted forced expiratory volume (ppFEV1) and Lung Clearance Index (LCI) recovery using Day 28 values compared to nearest pre-PEx baseline measure in both treatment arms.

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 2: Time to symptom recovery
Aikaikkuna: 28 days

Compare time to symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 3: Targeted adverse events
Aikaikkuna: 28 days

Compare targeted adverse events (participant report of antibiotic side effects during PEx period) between treatment arms.

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 4: Treatment-emergent CF microorganisms
Aikaikkuna: 28 days

Compare treatment-emergent CF microorganisms on clinical respiratory cultures between treatment arms.

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 5: Treatment with additional non-protocol assigned antibiotics
Aikaikkuna: 28 days

Compare treatment with additional non-protocol assigned antibiotics within the 28 days post-randomization between treatment arms.

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 6: Time to IV antibiotics following a randomized PEx
Aikaikkuna: 28 days

Compare time to IV antibiotics following a randomized PEx (using CF Foundation Patient Registry data, if available) between treatment arms.

28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 1
Aikaikkuna: 28 days

Measure the proportion of approached patients that enrolls.

28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 2
Aikaikkuna: 28 days

Measure the proportion of respiratory symptoms meeting randomization criteria.

28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 3
Aikaikkuna: 28 days

Measure the proportion of respiratory symptoms meeting randomization criteria resulting in treatment initiation within assigned arm.

28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 4
Aikaikkuna: 28 days

Through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences in order to understand motivations, benefits and challenges associated with assigned treatment arm.

28 days
Clinic Throat Swab Substudy 1: Metagenomic Sequencing
Aikaikkuna: 1 year

Use quantitative polymerase chain reaction (qPCR) and metagenomic sequencing to quantitatively define throat swab microbiology at baseline, at exacerbation diagnosis, and after treatment. Metagenomic sequencing analyzes the genomes of all microorganisms in a sample, providing a broad overview of the ecosystem's composition. It can be used to study the diversity of bacteria, detect the abundance of microbes, and study unculturable microorganisms.

1 year
Clinic Throat Swab Substudy 2: Microbiota Measures
Aikaikkuna: 1 year

Correlate throat microbiota measures (both pre-treatment microbial taxonomic or functional gene abundances, and changes in those abundances) with clinical outcome measures within antibiotic treatments.

1 year
Home Throat and Nasal Swab Substudy 1: Feasibility of Home Collection of Nasal Swabs for Viral Testing and Illness Frequency
Aikaikkuna: 28 days

Assess the feasibility of home collection of nasal swabs for viral testing at the time of pulmonary exacerbation (PEx) and determine the frequency of viral illness at the time of PEx diagnosis.

28 days
Home Throat and Nasal Swab Substudy 2: Feasibility of Home Collection of Throat Swabs for Bacterial testing
Aikaikkuna: 28 days

Assess the feasibility of home collection of throat swabs for bacterial testing at the time of pulmonary exacerbation (PEx).

28 days
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and Symptom recovery
Aikaikkuna: 28 days

Evaluate the association between the presence of viral illness and symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

28 days
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and FEV1
Aikaikkuna: 28 days

Evaluate the association between the presence of viral illness and spirometry-measured forced expiratory volume (FEV1) at Day 28.

28 days
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and antibiotic treatment.
Aikaikkuna: 28 days

Evaluate the association between the presence of viral illness and the percent of subjects in the tailored therapy arm requiring antibiotic treatment.

28 days
Home Throat and Nasal Swab Substudy 5: Bacterial Pathogen Identification, Frequency and Impact on Treatment Changes
Aikaikkuna: 28 days

Determine the concordance of bacteria identified on CF pathogen testing at the time of pulmonary exacerbation (PEx) compared to the most recent routine clinic visit. In addition, assess how frequently new bacterial pathogens are identified at the time of PEx and how this impacts treatment changes, including the need to change or add antibiotic therapy.

28 days
Remote Monitoring Substudy 1: Feasibility of Home Spirometry Use During PEx
Aikaikkuna: 28 days

Describe the feasibility and user acceptability of home spirometry during pulmonary exacerbations (PEx) in children with CF via survey of participants at the end of the study.

28 days
Remote Monitoring Substudy 2: Feasibility of BioButton Use During PEx
Aikaikkuna: 14 days

Describe the feasibility and user acceptability of BioButton use during pulmonary exacerbations in children with CF via survey of participants at the end of the study.

14 days
Remote Monitoring Substudy 3: Change in FEV1 by Home Spirometry
Aikaikkuna: 28 days

Describe the change from nearest baseline-state FEV1 to Day 0 exacerbation state measurement and the trajectory of change during the exacerbation state (through Day 28).

28 days
Remote Monitoring Substudy 4: Compare Home Spirometry vs. Clinic Spirometry Measures
Aikaikkuna: 28 days

Compare measurements and their change measured by home spirometry vs. clinic spirometry during the exacerbation state.

28 days
Remote Monitoring Substudy 5: BioButton-measured Change in Resting Heart Rate During PEx
Aikaikkuna: 14 days

Describe changes in resting heart rate from Day 0 to 14 of the exacerbation state.

14 days
Remote Monitoring Substudy 5: BioButton-measured Change in Resting respiratory rate During PEx
Aikaikkuna: 14 days

Describe changes in Resting respiratory rate from Day 0 to 14 of the exacerbation state.

14 days
Remote Monitoring Substudy 5: BioButton-measured Change in Activity Level During PEx
Aikaikkuna: 14 days

Describe changes activity level, measured using actigraphy, and summarized as the mean (SD) number of active minutes in a day, from Day 0 to 14 of the exacerbation state.

14 days
Remote Monitoring Substudy 5: BioButton-measured Change in Sleep During PEx
Aikaikkuna: 14 days

Describe changes in sleep time from Day 0 to 14 of the exacerbation state.

14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in resting heart rate During PEx with Baseline Averages
Aikaikkuna: 14 days

Compare changes in resting HR to averages from a 7-day period during baseline state.

14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Resting respiratory rate During PEx with Baseline Averages
Aikaikkuna: 14 days

Compare changes in BioButton-measured Resting respiratory rate to averages from a 7-day period during baseline state.

14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in activity level During PEx with Baseline Averages
Aikaikkuna: 14 days

Compare BioButton-measured change in activity level during pulmonary exacerbation (PEx) to averages from a 7-day period during baseline state.

14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Sleep During PEx with Baseline Averages
Aikaikkuna: 14 days

Compare BioButton change in sleep during PEx to averages from a 7-day period during baseline state.

14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Heart Rate (HR)
Aikaikkuna: 14 days

Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Heart Rate (HR). The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Respiratory rate
Aikaikkuna: 14 days

Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Respiratory rate. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Activity level
Aikaikkuna: 14 days

Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Activity level, measured with actigraphy. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Sleep duration
Aikaikkuna: 14 days

Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to sleep duration. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

14 days

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Yhteistyökumppanit

Tutkijat

  • Päätutkija: Margaret Rosenfeld, MD, MPH, Seattle Children's Hospital
  • Päätutkija: D. B. Sanders, MD, MS, Indiana University

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Sunnuntai 1. joulukuuta 2024

Ensisijainen valmistuminen (Arvioitu)

Torstai 30. joulukuuta 2027

Opintojen valmistuminen (Arvioitu)

Keskiviikko 28. helmikuuta 2029

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 14. lokakuuta 2024

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 21. lokakuuta 2024

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 23. lokakuuta 2024

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 9. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 6. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa